Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lilly Cuts Income Targets, Lifts Sales Forecast For FY21

10/26/2021 | 07:31am EST


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
12/03FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
RE
12/03Eli Lilly, AbCellera Land FDA's Expanded Emergency Use Approval for COVID-19 Antibody T..
MT
12/03Eli Lilly Gets FDA's Expanded Emergency Use Approval for Antibody Therapy to Treat COVI..
MT
12/03FDA Expands Emergency Use for Lilly Antibody Combination for Covid-19 to Include Infant..
DJ
12/03Eli Lilly Sees FDA Granting EUA of Two Monoclonal Antibodies for Treatment of COVID in ..
MT
12/03AbCellera Biologics Names New Chief Commercial Officer
MT
12/03Eli Lilly, Innovent Biologics' Cancer Drug Added to China's Updated National Reimbursem..
MT
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/02Innovent Biologics, Inc. and Eli Lilly and Company Announce Successful Expansion of Sin..
CI
12/02Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
RE
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 480 M - -
Net income 2021 6 130 M - -
Net Debt 2021 12 164 M - -
P/E ratio 2021 36,5x
Yield 2021 1,34%
Capitalization 223 B 223 B -
EV / Sales 2021 8,54x
EV / Sales 2022 8,34x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 245,58 $
Average target price 273,42 $
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY47.55%222 641
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ABBVIE INC.8.18%210 113